An observational study in Pulmonary Hypertension and Global Health, sponsored by University of Giessen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by University of Giessen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hypertension, Pulmonary by University of Giessen — 5 open to participants now, 5 under way, none of them phase 3. Hypertension, Pulmonary · University of Giessen.
Among the 13 studies in Hypertension, Pulmonary by University of Giessen, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2020, is one of 11 observational ones, and was the 11th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →5 of the 13 studies in Hypertension, Pulmonary by University of Giessen are open now, in 1 country. Recruiting first, the newest first:
University of Giessen · Sites in Germany
Ages 18+ · Healthy volunteers
University of Giessen · Sites in Germany
Ages 18+
University of Giessen · Sites in Germany
University of Giessen · Sites in Germany
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 2020.
This study's planned enrollment of 40,000 is above the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 57 across the 2 interventional studies, 500 across the 11 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Giessen is the lead sponsor of 95 studies on the registry; 22 are open to participants now.
1 of the studies in Hypertension, Pulmonary by University of Giessen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06409624University of GiessenAssociation Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Hypertension, Pulmonary by University of Giessen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center. Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.
PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center.
Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.
The data provided by PVRI-GoDeep will support academia to perform scientific projects in the field of PH. Pharmaceutical / commercial companies will be charged fee for access to PVRI-GoDeep data and / or analysis, thereby creating revenues exclusively devoted to support the PVRI mission and the registries entering their data into PVRI-GoDeep. All requests from academia or commercial companies are to be decided by the PVRI-GoDeep consortium, serving as Use and Access Committee.
Global cohort of patients with pulmonary hypertension (PH)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a diagnosis of pulmonary hypertension typically diagnosed via right heart catheterization.
Participating PH centers can optionally provide data about patients with exclusion of pulmonary hypertension
Global analysis of PH patients
Global comparison and analysis of the course of disease of PH patients
Time frame: From entry into the registry up to 10 years
Started Jan 2020 (actual). Primary completion is estimated for Jan 2050, 360 months after the start.
Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 360 months is above that.
Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Giessen